1714998-87-4
1714998-87-4
Chemical Structure
Tivozanib-d6
Synonym(s): AV-951-d6; KRN951-d6
- CAS No.: 1714998-87-4
- Formula:C22H13D6ClN4O5
- Molecular Weight:460.90
InChIKey: SPMVMDHWKHCIDT-XERRXZQWSA-N
SMILES: O=C(NC1=NOC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OC([2H])([2H])[2H])=C(OC([2H])([2H])[2H])C=C34)C=C2Cl
Biological Activity: Tivozanib-d6 (AV-951-d6) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tivozanib-d6 | Tivozanib-d6 (AV-951-d6) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tivozanib (Standard) | ≥98% | Tivozanib (Standard) is the analytical standard of Tivozanib. This product is intended for research and analytical applications. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tivozanib | 99.80% | Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Nakamura K, et al., KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66(18):9134-42. [Content Brief]
